Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788125 · ClinicalTrials.gov registry record · Phase 1
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
A Phase 1 study, sponsored by City of Hope Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00788125 is a Phase 1 study that was terminated before completion, run by City of Hope Medical Center. The registered enrollment target is 7 participants.
The verdict
NCT00788125, a Phase 1 study, was terminated before completion, sponsored by City of Hope Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with ifosfamide, carboplatin, and etoposide may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of dasatinib when given together with ifosfamide, carboplatin, and etoposide and to see how well they work in treating young patients with metastatic or recurrent malignant solid tumors.
Interventions
- GENETIC microarray analysis
- DRUG carboplatin
- DRUG dasatinib
- DRUG ifosfamide
- DRUG etoposide phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-09-03 |
| Est. Completion | 2022-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00788125
The ClinicalTrials.gov registry entry for NCT00788125 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which microarray analysis is the first listed.
NCT00788125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00788125 about?
NCT00788125 is a clinical study titled "Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors". RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividi...
What is the current status of trial NCT00788125?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2008-09-03. Estimated completion is 2022-07-30.
What interventions are being tested in trial NCT00788125?
The interventions under investigation include: microarray analysis (GENETIC), carboplatin (DRUG), dasatinib (DRUG), ifosfamide (DRUG), etoposide phosphate (DRUG).
Who is sponsoring clinical trial NCT00788125?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.